The combination of cytotoxic and molecularly targeted therapies - Can it be done?

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 445-454

  Jackman, Ann L ^a   Kaye, Stanley ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEASOME; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG POTENTIATION; DRUG TARGETING; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; INDIVIDUALIZATION; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; ONCOGENE; PATIENT CARE; PREDICTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL;

EID: 13344286962     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.012     Document Type: Review

References (73)

1. A. Gschwind et al. The discovery of receptor tyrosine kinases: Targets for cancer therapy Nat. Rev. Cancer 4 2004 361-370
2. P. Workman S.B. Kaye Translating basic cancer research into new cancer therapeutics Trends Mol. Med. 8 2002 S1-S9
3. B.J. Druker STI571 (Gleevec™) as a paradigm for cancer therapy Trends Mol. Med. 8 2002 14-18
4. E. Weisberg J.D. Griffen Resistance to imatinib (Glivec): Update on clinical mechanisms Drug Res. Updat. 6 2003 231-238
5. J. Mendelsohn Targeting the epidermal growth factor receptor for cancer therapy J. Clin. Oncol. 20 2002 S1-S13
6. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on nsclc Int. J. Radiat. Oncol. Biol. Phys. 58 2004 991-1002
7. J.G. Paez et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Sci. Exp. 2004 1-4
8. T.J. Lynch et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129-2139
9. P. Workman Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Lett. 206 2004 149-157
10. J. Adams The proteasome: A suitable antineoplastic target Nat. Rev. Cancer 4 2004 349-360
11. R. Kristeleit et al. Histone modification enzymes: Novel targets for cancer drugs Exp. Opin. Emerg. Drugs 9 2004 135-154
12. M.S. Gitler et al. Preclinical models for defining efficacy of drug combinations: Mapping the road to the clinic Mol. Cancer Ther. 2 2003 929-932
13. P. Workman Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment Biochem. Soc. Trans. 32 2004 393-396
14. J. Mendelsohn J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550-6565
15. A.W. Millar K.P. Lynch Rethinking clinical trials for cytostatic drugs Nat. Rev. Cancer 3 2003 540-545
16. B.F. El-Rayes P.M. LoRusso Targeting the epidermal growth factor receptor Br. J. Cancer 91 2004 418-424
17. L. Castillo et al. Pharmacological background of EGFR targeting Ann. Oncol. 15 2004 1007-1012
18. J.S. de Bono E.J. Rowinsky The ErbB receptor family: A therapeutic target for cancer Trends Mol. Med. 8 2002 S19-S26
19. R.S. Herbst P.A. Bunn Jr Targeting the epidermal growth factor receptor in non-small cell lung cancer Clin. Cancer Res. 9 2003 5813-5824
20. J-S. Chen et al. Strategies to target HER2/neu over expression for cancer therapy Drug Res. Updat. 6 2003 129-136
21. F. Ciardiello An update of new targets for cancer treatment: receptor-mediated signals Eur. Soc. Med. Oncol. 2002 29-38
22. R.S. Herbst D.M. Shin Monoclonal antibodies to target epidermal growth factor-positive tumours Cancer 94 2002 1593-1611
23. V. Grünwald M. Hidalgo Developing inhibitors of the epidermal growth factor receptor for cancer treatment J. Nat. Cancer Inst. 95 2003 851-867
24. J. Baselga et al. Mechanism of action of trastuzumab and scientific update Semin. Oncol. 28 2001 4-11
25. C.L. Arteaga Epidrmal growth factor receptor dependence in human tumours: More than just expression? Oncologist 7 2002 31-39
26. F. Ciardiello G. Tortora A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin. Cancer Res. 7 2001 2958-2970
27. M. Harries I. Smith The development and clinical use of trastuzumab (Herceptin) Endocr. Relat. Cancer 9 2002 75-85
28. C. Vogel et al. Efficacy and safety of trasuzumab as single agent first-line treatment of HER-2-overexpressing metastatic breast cancer J. Clin. Oncol. 3 2002 719-726
29. J. Baselga et al. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumour activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts Cancer Res. 58 1998 2825-2831
30. D.S. Slamon et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783-792
31. M.D. Pegram et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241-2251
32. M.D. Pegram et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J. Natl. Cancer Inst. 96 2004 739-749
33. R.S. Herbst D.M. Shin Monoclonal antibodies to target epidermal growth factor receptor-positive tumors Cancer 2002 1593-1611
34. F. Ciardiello et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin. Cancer Res. 5 1999 909-916
35. C.J. Bruns et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanism Clin. Cancer Res. 6 2000 1936-1948
36. M.C. Prewett et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CTP-11) against human colorectal tumor xenografts Clin. Cancer Res. 8 2002 994-1003
37. K. Inoue et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin. Cancer Res. 6 2000 4874-4884
38. Z. Fan et al. Antitumour effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Res. 53 1993 4637-4642
39. J. Baselga et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J. Natl. Cancer Inst. 85 1993 1327-1333
40. D. Cunningham et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 351 2004 337-345
41. P. Rougier et al. Cetuximab and FOLFIRI as first line treatment of metastatic colorectal cancer Proc. Am. Soc. Clin. Oncol. 22 2004 248
42. J.M. Tabernero et al. An international Phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil/folinic acid (FOLFOX-4) in the first line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor. Preliminary results Proc. Am. Soc. Clin. Oncol. 2004 22 (abstract number 3512)
43. D. Melisi et al. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments Endocr. Relat. Cancer 11 2004 51-68
44. M.L. Amador M. Hidalgo Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer Clin. Colorectal Cancer 4 2004 51-62
45. D.M. Shin et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin. Cancer Res. 7 2002 1204-1213
46. B.A. Burtness et al. Phase III trial comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor antibody C225 on patients with metastatic/recurrent head and neck cancer Am. Soc. Clin. Oncol. 2002 20 (abstract number 901)
47. J.A. Bonner et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab Proc. Am. Soc. Clin. Oncol. 2004 22 (abstract number 5507)
48. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol. Ther. 82 1999 241-250
49. G. Giaccone et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1 J. Clin. Oncol. 22 2004 777-784
50. R.S. Herbst et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 J. Clin. Oncol. 22 2004 785-794
51. R.S. Herbst et al. TRIBUTE - a phase III trial of erlotinib HCL (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer Proc. Am. Soc. Clin. Oncol. 2004 22 (abstract number 7011)
52. F.A. Shepherd et al. A randomised placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial Proc. Am. Soc. Clin. Oncol. 2004 22 (abstract number 7022)
53. N. Magné et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer Br. J. Cancer 86 2002 819-827
54. F.M. Sirotnak et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR Tyrosine kinase Clin. Cancer Res. 6 2000 4885-4892
55. F. Ciardiello et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2004 2053-2063
56. M. Sumitomo et al. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway Clin. Cancer Res. 10 2004 794-801
57. V.A. Pollack et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice J. Pharm. Exp Ther. 291 1999 739-748
58. D. Raben et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Semin. Oncol. 29 2002 37-46
59. D.B. Solit et al. Pulsatile administration of the EGF receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitising tumours to taxol Clin. Cancer Res. 9 16 part 2 (Suppl.) 2003 6089s
60. H.X. Chen Expanding the clinical development of bevacizumab Oncologist 9 2004 27-35
61. H. Hurwitz et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335-2342
62. T. Tauchi K. Ohyashiki Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukaemia Int. J. Hemet. 79 2004 434-440
63. G. Cartron et al. From the bench to the bedside: Ways to improve rituximab efficacy Blood 104 2004 2635-2642
64. A.J. Grillo-Lopez Rituximab (Rituxan/MabThera): The first decade Expert Rev. Anticancer Ther. 3 2003 767-779
65. S.M. Sebti C.J. Der Searching for the elusive targets of farnesyltransfersase inhibitors Nat. Rev. Med. 3 2003 945-951
66. I. Vivanco C.L. Sawyers The phosphatidylinostol 3-kinase-AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489-501
67. M-A. Bjornsti P.J. Houghton The Tor pathway: A target for cancer therapy Nat. Rev. Cancer 4 2004 335-348
68. P. Workman Cancer genome targets: RAF-ing up tumour cells to overcome oncogene addiction Expert Rev. Anticancer Ther. 2 2002 611-614
69. E.A. Sausville et al. Clinical development of 17-allylamino, 17-demethoxygeldanamycin Curr. Cancer Drug Targets 3 2003 377-383
70. B.W. Dymock et al. Inhibitors of HSP90 and other chaperones for the treatment of cancer Expert Opin. Ther. Patents 14 2004 837-847
71. B-B.S. Zhou J. Bartek Targeting the checkpoint kinases: chemosensitisation versus chemoprotection Nat. Rev. Cancer 4 2004 216-225
72. S.J. McClue et al. In vitro and in vivo antitumour properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int. J. Cancer 102 2002 463-468
73. J.K. Smith et al. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy Oncol. Res. 14 2004 175-225